Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

IDEC-Y2B8

A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. IDEC-Y2B8 contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. IDEC-Y2B8 is a type of radioimmunoconjugate. Also called 90Y-ibritumomab tiuxetan, 90Y-Zevalin, and yttrium Y 90-ibritumomab tiuxetan.
Search NCI's Dictionary of Cancer Terms